Signal from the log
KaliVir Immunotherapeutics
14 M$ · Series A · United States · Biotech
Biotech de Pittsburgh en phase clinique. Elle construit des virus oncolytiques à partir du virus de la vaccine, dont VET3-TGI, qui se réplique dans les cellules tumorales et y exprime l'IL-12 et un inhibiteur du TGF bêta, en essai de phase 1/1b.
Verified
Announced on , logged by the watch of 19 August 2026.
- Operation
- Funding round
- Announced amount
- 14 M$
- Stage
- Series A
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Company K Partners , with SV Investment , Flexus Partners
Provenance
Source businesswire,pulse2
Logged on 19 August 2026
Description Written in French during the watch run. Based on the headline as relayed by the source, without reading the issuer's press release.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.